ICON plc, and the National Clinical Trials and Research Centre (NCTRC) at the National Taiwan University Hospital, have entered a collaboration to enhance the set-up and management of clinical studies in Taiwan. The two companies will work together on study start-up, site feasibility, key site and investigator selection, patient recruitment, as well as work together to further enhance clinical research standards in Taiwan.
“We are very pleased to be collaborating with the NCTRC who are at the forefront of clinical research in Taiwan,” said Wei Ming Goh, ICON’s vice president, Asia-Pacific. “Our customers are increasingly looking to include Taiwan in their clinical programs and are expecting fast timelines for study start-up and patient recruitment. By combining the proven expertise of ICON and NCTRC in the region, we can further accelerate study timelines which will benefit our customers and also enhance the Taiwanese clinical trials industry.”
“The aim of this partnership is to accelerate new drug development and new treatments for diseases and we hope to achieve this by leveraging our respective strengths,” said Professor Chan Wing Kai, director of NCTRC. “We are happy to be collaborating with ICON, a leading clinical research organization that has proven experience in both global and local clinical development programs.”